News
More Info
- About Biotec Pharmacon
- Beta Glucans
- Marine Enzymes
- Investors
- News
- Meet us at the EWMA on 23-25 May 2012 in Vienna
- Relay team from Biotec Pharmacon in Holmenkollstafetten
- ArcticZymes AS finalizes its protection of the SAP patent family
- Webcast: Presentation of Q1 2012
- Notice of General Meeting 2012
- Kort redegjørelse om børsmeldinger fra Biotec Pharmacon
- ArcticZymes AS Files New Enzyme Patent Application
- New patents solidify efforts in cancer adjuvant therapy
- Successful production of the first technical batch of Woulgan® Biogel completed
- Webcast: Presentation of results for Q4 2011
- Biotec BetaGlucans at Conferences
- ArcticZymes establishes US subsidiary
- SBG - 30 års erfaring med glukaners positive virkning på immunforsvaret
- Webcast: Presentation of results for Q3 2011
- New Patent for Cancer Adjuvant Therapy Issued
- We congratulate this year's Nobel Laureates in Physiology or Medicine
- Vi gratulerer årets Nobelprisvinnere i medisin
- Biotec Pharmacon and Affymetrix sign new agreement for the SAP enzyme
- Science Daily: ”Baker’s Yeast Substance Can Aid Healing”
- Webcast & Presentation Q2-2011
- Report on neuroblastoma study
- Q1-2011 Presentation as WebCast
- Biotec Pharmacon at Anglonordic Biotech Conference
- Notice of Annual General Meeting 2011
- ArcticZymes has been awarded a research grant of MNOK 7.2
- Shares registered in VPS Registrar
- Q4-2010 Presentation as WebCast
- Subsequent offering - subscription period ends today
- VI HAR FLYTTET - WE HAVE MOVED
- Subsequent Offering - Information
- Biotec Pharmacon receives promising interim results from animal study
- Approved prospectus
- Notice for Extraordinary General Meeting of Biotec Pharmacon ASA on January 19, 2011
- Private Placement successfully completed
- Biotec Pharmacon's patent application referring to a combination therapy for cancer treatment has been granted in Mexico
- Biotec Pharmacon and University of Tromsø extend cooperation to include the MARZymes project
- Biotec Pharmacon receives promising results from animal study of SBG which confirms initial findings announced in the Q2 Report
- Patent granted in USA
- Q1-2010 Presentation as WebCast
- Ordinary General Meeting
- Biotec Marine Biochemicals reviewed in PCR Insider - the leading journal for PCR users
- Svein Lien appointed new CEO of Biotec Pharmacon ASA
- Biotec Pharmacon presenting re-established platform at BIO-Europe 2010
- Testing SBG packaging containers after weak results from oral mucositis study
- Biotec Pharmacon to focus on bio-pharmaceuticals - sells Immunocorp Consumer Health AS
- Extraordinary General Meeting
- Biotec Pharmacon realigns strategy and reduces workforce
- Phase III results with SBG for diabetic foot ulcer not positive
- Databases locked in both the phase III clinical studies with SBG for diabetic foot ulcer
- Presenting at Bio Investor Forum in San Francisco and at Bio Europe 2009 in Vienna
- 3Q presentation as webcast
- Presenting at Life Science Conference in New York and at Bio-Business Seminar in Zürich
- Biotec Pharmacon at both Biotech in Europe and BioPharm America in September
- Completed patient inclusion in phase III study for oral mucositis
- Biotec Pharmacon presents its cancer program at ECCP in Toulouse
- The Cold Rush
- Settlement between Biotec Pharmacon ASA and Biothera
- Phase III oral mucositis study proceeds as planned after interim analysis
- U.S patent court case scheduled for 14 September 2009
- Jan Buch Andersen heading up newly established Biotec Marine Biochemicals AS
- Phase III diabetic ulcer program proceeds as planned after interim analysis
- Completed patient inclusion in both phase III diabetic ulcer studies
- Completed patient inclusion in the first phase III diabetic ulcer study
- Biotec Pharmacon at BIO- Europe Spring 2009 in Milan
- Favourable ruling for Biotec Pharmacon in U.S patent case
- Rapport fra Sloan-Kettering studien
- PRELIMINARY RESULTS FROM THE SLOAN-KETTERING CLINICAL STUDY
- COMPLETED SHARE ISSUE AND SALE OF TREASURY SHARES
- CONTEMPLATED DIRECTED EQUITY ISSUE
- BIOTEC PHARMACON ENTERS PHASE III WITH THE DIABETIC ULCERS INDICATION
- BIOTEC PHARMACON ENTERS PHASE III WITH THE ORAL MUCOSITIS INDICATION
- Biotec Pharmacon kommersiell partner i Senter for Forskningsdrevet Innovasjon i Tromsø
- Poster presentation at CHI's 3rd annual qPCR conference
- Positive resultater fra diabetessårstudien
- * More » Positive resultater fra oral mukosittstudien
- Biotec Pharmacon completes patient enrollment in phase II clinical trial for treatment of diabetic ulcers
- Good progress in ongoing clinical trials
- New clinical study for treatment of diabetic foot ulcers
- Biotec Pharmacon to trial SBG/Rituxan combination therapy at the Radium Hospital
- Biotec Pharmacon to start SBG trials with Herceptin
